David Cohn E MD

David Cohn E MD
ProfessorCollege of Medicinecohn.30@osu.edu
M210 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7642Fax: (614) 293-3078
  • Translational Therapeutics

General Research Interest

I am interested in gynecologic cancers, from both a clinical, translational and basic science perspective.  The division of gynecologic oncology has many rich research collaborations with other members of the CCC. 

Research Description

My research focus includes identification of novel biomarkers in ovarian cacner for early detection and prevention.  We have investigated the role of micrRNA from blood as a biomarker for ovarian cancer, and have developed a vaccine targeting pro-angiogenic molecules in this disease.  Furtheromre, we are investigating the role of the TGF beta pathway in cervical cancer susceptibility as well as the ability of lyopholized black raspberries to prevent cervical cancer.

Transinstitutional Work

We are collaborating with the Fred Hutchinson in the investigation of microRNAs as ovarian cancer biomarkers, and with Washington University and the University of West Virginia in the identification of TGF beta pathways that underlie cervical cancer.

Current Publications

  • McCann GA, Cohn DE, Jewell EL, Havrilesky LJLymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: a cost-utility analysis.Gynecol Oncol in press 12/2/2014
  • Lee JY, Cohn DE, Kim Y, Lee TJ, Barnett JC, Kim JW, Jeon YW, Kim K, Park SM, Kang SThe cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: Insights from the US and Korean healthcare systems.Gynecol Oncol in press 10/29/2014
  • Cohn DE, Barnett JC, Wenzel L, Monk BJ, Burger RA, Straughn JM Jr, Myers ER, Havrilesky LJA cost-utility analysis of an NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected Quality-of-life scores in an economic model of treatment of ovarian cancer.Gynecol Oncol in press 10/23/2014
  • Joehlin-Price AS, Elkins CT, Stephens JA, Cohn DE, Knobloch TJ, Weghorst CM, Suarez AAComprehensive evaluation of caspase-14 in vulvar neoplasia: An opportunity for treatment with black raspberry extract.Gynecol Oncol in press 9/22/2014
  • Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJPolymerase ɛ (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing.Cancer in press 9/15/2014
  • Neff R, McCann GA, Carpenter KM, Cohn DE, Noria S, Mikami D, Needleman BJ, O'Malley DMIs bariatric surgery an option for women with gynecologic cancer? Examining weight loss counseling practices and training among gynecologic oncology providers.Gynecol Oncol 134 540-5 9/1/2014
  • Li Q, Cohn D, Waller A, Backes F, Copeland L, Fowler J, Salani R, O'Malley DOutpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.Gynecol Oncol in press 8/7/2014
  • Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJA phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.Gynecol Oncol 134 262-6 8/1/2014
  • Martin DD, Tierney BJ, Eisenhauer EL, Cohn DE, O'Malley DM, Salani R, Copeland LJ, Fowler JM, Backes FJ, Billingsley CCDoes intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Gynecol Oncol in press 7/30/2014
  • Tierney BJ, McCann GA, Naidu S, Rath KS, Saini U, Wanner R, Kuppusamy P, Suarez A, Goodfellow PJ, Cohn DE, Selvendiran KAberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.Gynecol Oncol in press 7/16/2014
  • Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer ELFeasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.Int J Gynecol Cancer 24 682-6 5/1/2014
  • Selvendiran K, Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DEHO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.Cancer Res 74 2316-27 4/15/2014
  • Cohn DESurgery or chemoradiation for stage IB cervical cancer? How cost effectiveness impacts a complex decision.J Gynecol Oncol 25 79-80 4/1/2014
  • Suarez AA, Joehlin-Price AS, Perrino CM, Stephens J, Backes FJ, Goodfellow PJ, Cohn DEMismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.Gynecol Oncol 133 43-7 4/1/2014
  • Brasky TM, Neuhouser ML, Cohn DE, White EAssociations of long-chain ω-3 fatty acids and fish intake with endometrial cancer risk in the VITamins And Lifestyle cohort.Am J Clin Nutr 99 599-608 3/1/2014
  • DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJPhase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.J Clin Oncol 32 458-64 2/10/2014
  • Randolph LK, McCann GA, Billingsley C, Hopkins MP, Huffman LB, Cohn DE, Hundley AFOptions for repair of rectus abdominis myocutaneous perineal/vaginal flap prolapse: A case series.Gynecol Oncol Case Rep 7 1-3 1/1/2014
  • Zighelboim I, Mutch DG, Knapp A, Ding L, Xie M, Cohn DE, Goodfellow PJHigh frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers.Hum Mutat 35 63-5 1/1/2014
  • Liang MI, Rosen MA, Rath KS, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DEReducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.Gynecol Oncol 131 508-11 12/1/2013
  • Alvarez Secord A, Cohn DE, Leath CA 3rd, Myers ER, Havrilesky LJ, Barnett JCCost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.Cancer 119 3653-61 10/15/2013
  • Lancaster J, Odunsi K, Wakabayashi M, Goff BA, Cohn DE, Leitao M, Levenback C, Berkowitz R, Roman L, Lucci J, Kim SReporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative.Gynecol Oncol 130 403-6 9/1/2013
  • Smith B, Cohn DE, Clements A, Tierney BJ, Straughn JM JrIs the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.Gynecol Oncol 130 416-20 9/1/2013
  • Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JSMulticenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.Gynecol Oncol 130 64-8 7/1/2013
  • Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23 833-8 6/1/2013
  • Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino REtiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.Gynecol Oncol 129 277-84 5/1/2013
  • McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129 135-9 4/1/2013
  • Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129 103-6 4/1/2013
  • Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian CPhase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol 129 22-7 4/1/2013
  • Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Chan J, Cho KR, McMillian NR, Hughes M, National Comprehensive Cancer Network, Apte SM, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL 2nd, Han E, Huh WK, Lurain JR 3rd, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Tillmanns T, Valea FACervical cancer.J Natl Compr Canc Netw 11 320-43 3/1/2013
  • Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161 156-64 3/1/2013
  • Clements AE, Tierney BJ, Cohn DE, Straughn JM JrIs selective lymphadenectomy more cost-effective than routine lymphadenectomy in patients with endometrial cancer?Gynecol Oncol 128 166-70 2/1/2013
  • Hess LM, Brady WE, Havrilesky LJ, Cohn DE, Monk BJ, Wenzel L, Cella DComparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study.Gynecol Oncol 128 175-80 2/1/2013
  • Brudie LA, Backes FJ, Ahmad S, Zhu X, Finkler NJ, Bigsby GE 4th, Cohn DE, O'Malley D, Fowler JM, Holloway RWAnalysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery.Gynecol Oncol 128 309-15 2/1/2013
  • Brasky TM, Moysich KB, Cohn DE, White ENon-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort.Gynecol Oncol 128 113-9 1/1/2013
  • Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran KSafe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs.J Ovarian Res 6 35 1/1/2013
  • Backes FJ, Tierney BJ, Eisenhauer EL, Bahnson RR, Cohn DE, Fowler JMComplications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: time to change back?Gynecol Oncol 128 60-4 1/1/2013
  • McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128 44-8 1/1/2013
  • Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Toland AE, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT, HEBON, EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Lubinski J, Durda K, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, CIMBA, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, kConFab Investigators, Radice P, Schmutzler RK, SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ, GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A, BCFR, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VSGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.PLoS Genet 9 e1003212 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu